| 0.9509 0.051 (5.62%) | 10-21 13:34 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.46 | 1-year : | 1.78 |
| Resists | First : | 1.25 | Second : | 1.52 |
| Pivot price | 1.11  |
|||
| Supports | First : | 0.8 | Second : | 0.66 |
| MAs | MA(5) : | 0.93 |
MA(20) : | 1.16 |
| MA(100) : | 1.54 |
MA(250) : | 1.79 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 21.3 |
D(3) : | 16.2 |
| RSI | RSI(14): 28.7 |
|||
| 52-week | High : | 3.88 | Low : | 0.8 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ AIMD ] has closed above bottom band by 24.4%. Bollinger Bands are 16.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.92 - 0.92 | 0.92 - 0.93 |
| Low: | 0.89 - 0.89 | 0.89 - 0.9 |
| Close: | 0.89 - 0.9 | 0.9 - 0.91 |
Ainos, Inc. operates as a healthcare technology company, specializing in point-of-care diagnostics and the development of safe, novel treatments for various disease indications. Its current portfolio encompasses a COVID-19 antigen rapid test kit, which integrates with a cloud-based test management platform known as the Ainos App, offering both personal and enterprise applications. Other diagnostic developments include a COVID-19 nucleic acid test and point-of-care testing for volatile organic compounds. Furthermore, the company is progressing with Very Low-Dose Oral Interferon Alpha, an oral formulation engineered to leverage the wide therapeutic applications of IFN-a, and is actively developing a Synthetic RNA (sRNA) technology platform in Taiwan. Established in 1984, this San Diego, California-based firm was formerly known as Amarillo Biosciences, Inc. until its rebranding to Ainos, Inc. in May 2021.
Fri, 16 Oct 2026
Three board classes take effect at Ainos (AIMD); its CEO’s board term ends at the 2028 annual meeting. - Stock Titan
Thu, 15 Oct 2026
Ainos' Stock Sinks To US$0.96, But Insiders Sold Even Lower - Simply Wall Street
Wed, 30 Sep 2026
Ainos Completes VELDONA Technology Transfer, Triggering $600,000 License Payment - newswire.com
Tue, 29 Sep 2026
Ainos, Inc. (AIMD) Delivers 1,400 AI Nose Units Under $2.1M Contract - TradingView
Tue, 29 Sep 2026
Ainos Completes Delivery of 1,400 AI Nose Systems to ASE Under $2.1 Million, Three-Year Contract - Yahoo Finance
Fri, 25 Sep 2026
AIMD - AINOS Inc. | News - OTC Markets
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 2 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 7.38e+006 (%) |
| Held by Institutions | 2.4e+006 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 10710 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2.54 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 894 % |
| Return on Equity (ttm) | 135.5 % |
| Qtrly Rev. Growth | -196.4 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -0.01 |
| EBITDA (p.s.) | -0.01 |
| Qtrly Earnings Growth | -9e+006 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0.9 |
| Price to Book value | -0.38 |
| Price to Sales | -43101.1 |
| Price to Cash Flow | 0 |
| Dividend | 41260 |
| Forward Dividend | 20460 |
| Dividend Yield | 4330390% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|